📊 OSTX Key Takeaways
Is OS Therapies Inc (OSTX) a Good Investment?
OS Therapies faces imminent insolvency with negative stockholders' equity (-$6.1M), catastrophic liquidity crisis (0.03x current ratio), and only $270K cash against $28.8M net losses. At current burn rates, the company has less than 2 weeks of cash runway and lacks capacity to fund operations without immediate external capital. The combination of pre-revenue status, balance sheet insolvency, and near-zero liquid reserves creates extreme going-concern risk.
Why Buy OS Therapies Inc Stock? OSTX Key Strengths
- Pre-revenue status is normal for early-stage biotech/pharmaceutical companies
- Recent insider activity (8 Form 4 filings) may indicate some management engagement
- Operating in pharmaceutical sector has potential long-term value if pipeline succeeds
OSTX Stock Risks: OS Therapies Inc Investment Risks
- Negative stockholders' equity indicates technical insolvency on balance sheet
- Critical liquidity crisis with 0.03x current ratio - insufficient to cover liabilities
- Only $269.8K cash with $28.8M annual net losses - less than 2 weeks operational runway
- No revenue generation; 100% dependent on capital raises or asset liquidation
- Severe risk of dilutive financing required for survival
- Going concern risk - company may be unable to fund normal operations
- Liabilities ($11.9M) exceed assets ($6.8M) by $5.1M
Key Metrics to Watch
- Cash balance and monthly burn rate
- Ability to secure capital injection or financing
- Operating expenses and cost containment progress
- Clinical trial milestones and regulatory pathway updates
- Share dilution from equity financings
- Total liabilities and accounts payable aging
- Timeline to revenue-generating assets or cash-generating events
OS Therapies Inc (OSTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
OSTX Profit Margin, ROE & Profitability Analysis
OSTX vs Healthcare Sector: How OS Therapies Inc Compares
How OS Therapies Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is OS Therapies Inc Stock Overvalued? OSTX Valuation Analysis 2026
Based on fundamental analysis, OS Therapies Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
OS Therapies Inc Balance Sheet: OSTX Debt, Cash & Liquidity
OSTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: OS Therapies Inc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.28 indicates the company is currently unprofitable.
OSTX Revenue Growth, EPS Growth & YoY Performance
OS Therapies Inc Dividends, Buybacks & Capital Allocation
OSTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for OS Therapies Inc (CIK: 0001795091)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OSTX
What is the AI rating for OSTX?
OS Therapies Inc (OSTX) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are OSTX's key strengths?
Claude: Pre-revenue status is normal for early-stage biotech/pharmaceutical companies. Recent insider activity (8 Form 4 filings) may indicate some management engagement.
What are the risks of investing in OSTX?
Claude: Negative stockholders' equity indicates technical insolvency on balance sheet. Critical liquidity crisis with 0.03x current ratio - insufficient to cover liabilities.
What is OSTX's revenue and growth?
OS Therapies Inc reported revenue of N/A.
Does OSTX pay dividends?
OS Therapies Inc does not currently pay dividends.
Where can I find OSTX SEC filings?
Official SEC filings for OS Therapies Inc (CIK: 0001795091) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OSTX's EPS?
OS Therapies Inc has a diluted EPS of $-0.98.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OSTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, OS Therapies Inc has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OSTX stock overvalued or undervalued?
Valuation metrics for OSTX: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy OSTX stock in 2026?
Our dual AI analysis gives OS Therapies Inc a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OSTX's free cash flow?
OS Therapies Inc's operating cash flow is $-14.2M, with capital expenditures of $466.4K.
How does OSTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.03 (avg: 2).